+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID06597721

Phase 1 Study Evaluating ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Adults With Advanced Solid Tumors

Led by Adcendo ApS · Updated on 2026-09-09

210

Participants Needed

14

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating ADCE-T02, an investigational tissue factor targeted antibody-drug conjugate, in adults with advanced solid tumors including head and neck squamous cell carcinoma HNSCC and pancreatic ductal adenocarcinoma PDAC. This phase 1 study aims to find the maximum tolerated dose, recommended dose, and assess the safety and tolerability of ADCE-T02 when given alone. The study includes patients who have progressed after at least one systemic therapy. Participants receive ADCE-T02 intravenously at different dose levels to determine the optimal dose for further studies. The trial includes a dose escalation phase followed by an expansion phase for specific tumor types. Treatment is given as a single therapy, and dosing schedules vary to assess safety and effects. During the study, participants undergo regular assessments including measurement of tumor response using RECIST criteria, monitoring for adverse events, and laboratory tests to evaluate organ function and drug levels. Researchers will track outcomes such as overall response rate, disease control, progression-free survival, and presence of anti-drug antibodies for up to 24 months. Safety and tolerability are closely monitored throughout the study duration.

CONDITIONS

Brief Title

ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

Research Team

S

Sherri Paxton

S

Sarah Berardini

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here